Catalyst Wire Dossier Catalyst Wire Dossier

Silevertinib

· Black Diamond Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Silevertinib, covering 2025-12-09 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII [Phase 2]

See pricing